In conclusion, our results indicate that high RalA GTPase activity results in malignant transformation and IM resistance in CML cells, and thus RalA could be a therapeutic target for CML. The gene discussed is RALA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.